Table 1.
Patients’ characteristics.
| Overall (N = 288) | SII stratified at 240 | SII stratified at 150 | |||||
|---|---|---|---|---|---|---|---|
| SII <240 (n = 144) | SII ≥240 (n = 144) | p | SII <150 (n = 67) | SII ≥150 (n = 221) | p | ||
| Female | 150 (52.1%) | 70 (48.6%) | 74 (51.4%) | 0.238 | 33 (49.3%) | 117 (52.9%) | 0.597 |
| Age (years) | 49.0 (42.0–56.0) | 50.5 (44.0–56.0) | 47.5 (36.5–55.0) | 0.125 | 51.0 (44.0–56.0) | 49.0 (40.0–55.0) | 0.220 |
| Age ≥ 50 years | 138 (47.9%) | 76 (52.8%) | 62 (43.1%) | 0.099 | 37 (55.2%) | 101 (45.7%) | 0.172 |
| Liver cirrhosis | 23 (8.0%) | 19 (13.2%) | 4 (2.8%) | 0.001 | 9 (13.4%) | 14 (6.3%) | 0.060 |
| HCV RNA(lg10 IU/L) | 6.0 (5.2–6.4) | 6.0 (5.3–6.5) | 6.0 (5.2–6.5) | 0.503 | 6.0 (5.5–6.4) | 6.0 (5.2–6.5) | 0.919 |
| HCV genotype | 0.905 | 0.385 | |||||
| 1 | 120 (41.7%) | 63 (43.8%) | 57 (39.6%) | 33 (49.3%) | 87 (39.4%) | ||
| 2 | 21 (7.3%) | 9 (6.3%) | 12 (8.3%) | 2 (3.0%) | 19 (8.6%) | ||
| 3 | 112 (38.9%) | 55 (38.2%) | 57 (39.6.2%) | 25 (37.3%) | 87 (39.4%) | ||
| 6 | 26 (9.0%) | 12 (8.3%) | 14 (9.7%) | 5 (7.5%) | 21 (9.5%) | ||
| Unknown | 9 (3.1%) | 5 (3.5%) | 4 (2.8%) | 2 (3.0%) | 7 (3.2%) | ||
| Total bilirubin (μmol/L) | 12.5 (9.5–16.8) | 13.2 (9.8–18.3) | 11.9 (9.2–15.4) | 0.013 | 12.8 (9.5–18.3) | 9.5 (12.4–16.1) | 0.795 |
| Alanine aminotransferase (×ULN) | 1.4 (0.9–2.4) | 1.6 (0.9–2.9) | 1.2 (0.8–2.1) | 0.007 | 1.6 (0.8–3.4) | 1.3 (0.9–2.4) | 0.265 |
| Alanine aminotransferase >2 × ULN | 100 (34.7%) | 60 (41.7%) | 40 (27.8%) | 0.013 | 27 (40.3%) | 73 (33.0%) | 0.274 |
| Aspartate aminotransferase (×ULN) | 50.0 (33.0–79.0) | 60.0 (40.3–88.0) | 44.5 (31.0–63.0) | 0.001 | 65.0 (36.0–100.0) | 48.0 (32.5–69.0) | 0.044 |
| Aspartate aminotransferase-to-alanine aminotransferase ratio ≥ 1 | 89 (30.9%) | 51 (35.4%) | 38 (26.4%) | 0.097 | 25 (37.3%) | 64 (29.0%) | 0.195 |
| Albumin (g/L) | 44.3 (41.1–47.0) | 43.5 (40.1–46.8) | 45.1 (42.0–47.2) | 0.005 | 43.5 (36.5–46.5) | 44.7 (41.9–47.2) | 0.108 |
| Serum creatinine (×ULN) | 0.6 (0.5–0.7) | 0.6 (0.5–0.7) | 0.6 (0.5–0.7) | 0.249 | 0.6 (0.5–0.7) | 0.6 (0.5–0.7) | 0.484 |
| Platelet (×109/L) | 144.0 (103.0–189.5) | 106.0 (76.5–148.8) | 183.5 (142.0–220.5) | <0.001 | 85.0 (58.0–105.0) | 163.0 (121.5–202.0) | <0.001 |
| Platelet >100 × 109/L | 223 (77.4%) | 88 (61.1%) | 135 (93.8%) | <0.001 | 22 (32.8%) | 201 (91.0%) | <0.001 |
| SII | 238.2 (153.0–358.2) | 153.3 (104.7–201.3) | 357.5 (295.2–462.8) | <0.001 | 97.8 (72.5–124.4) | 289.4 (213.3–391.5) | <0.001 |
| Ribavirin administration | 108 (37.5%) | 51 (35.4%) | 57 (39.6%) | 0.465 | 24 (35.8%) | 84 (38.0%) | 0.746 |
| SVR12 | 287 (99.7%) | 143 (99.3%) | 144 (100.0%) | >0.99 | 66 (98.5%) | 221 (100.0%) | 0.233 |
| Outcome of liver fibrosis | |||||||
| Non-improved APRI | 239 (83.0%) | 101 (70.1%) | 138 (95.8%) | <0.001 | 35 (52.2%) | 204 (92.3%) | <0.001 |
| Non-improved FIB-4 | 252 (87.5%) | 114 (79.2%) | 138 (95.8%) | <0.001 | 50 (74.6%) | 202 (91.4%) | <0.001 |
SII, systemic immune-inflammation index; HCV, hepatitis C virus; ULN, upper limit of normal; SVR12, HCV RNA less than 15 IU/mL 12 weeks after cessation of antiviral therapy; FIB-4, fibrosis-4; APRI, aspartate aminotransferase-to-platelet ratio index. Quantitative data are presented as median (interquartile range) and are compared using Mood’s median test. Qualitative data are presented as frequencies (proportion) and are compared using the chi-squared test.